Who
Elissa J. Schwartz
Director
Company insider
Files Form 4 as: Director, Galectin Therapeutics.
In numbers
- Trades disclosed
- 9
- Buys
- 1
- Sells
- 0
- Bought
- $2,000
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 25 Mar 2021
- Last trade
- 16 Jan 2026
- Last filed
- 21 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jan 2026filed 21 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 23 Jan 2025filed 27 Jan 2025 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 24 Jan 2024filed 7 Feb 2024 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 26 Jan 2023filed 30 Jan 2023 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 24 Jan 2022filed 25 Jan 2022 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 21 Jan 2022filed 24 Jan 2022 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $2,0001,000 at $2.00 | filing |
| 25 Mar 2021filed 31 Mar 2021 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 25 Mar 2021filed 31 Mar 2021 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.